ADARx Pharmaceuticals (ADRX) vs Agios Pharmaceuticals (AGIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agios Pharmaceuticals is the larger company by market cap ($1.89 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | AGIO |
|---|---|---|
| Share price | $17.00 | $31.72 |
| Market cap | $1.82B | $1.89B |
| 1-day change | -1.90% | -0.22% |
| YTD return | — | +16.79% |
| 1-year return | — | -22.22% |
| 5-year return | — | -31.31% |
| EPS (TTM) | $-1.16 | $-7.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $46.00 |
| 52-week low | $16.64 | $22.24 |
| Distance from 52-week high | -26.76% | -31.04% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +45.02% |
| Average volume | 1.34M | 1.05M |
| Shares outstanding | 106.80M | 59.70M |
| Employees | 100 | 539 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
ADRX vs AGIO FAQ
Which is bigger, ADARx Pharmaceuticals or Agios Pharmaceuticals?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.89B compared with $1.82B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Agios Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.